These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19329547)

  • 1. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):410-8. PubMed ID: 18635707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies.
    Krishnan S; Montcrief S
    Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):231-40. PubMed ID: 17845504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
    Krishnan SM; Stark JG
    Curr Med Res Opin; 2008 Jan; 24(1):33-40. PubMed ID: 18021493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
    Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
    Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
    Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
    J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
    Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
    Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
    Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
    Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
    Adler LA; Alperin S; Leon T; Faraone S
    Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the safety of lisdexamfetamine dimesylate.
    Coghill DR; Caballero B; Sorooshian S; Civil R
    CNS Drugs; 2014 Jun; 28(6):497-511. PubMed ID: 24788672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisdexamfetamine: a prodrug stimulant for ADHD.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Aug; 46(8):19-22. PubMed ID: 18777964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Adler LA; Alperin S; Leon T; Faraone SV
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
    Ermer JC; Pennick M; Frick G
    Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.